Treatments Outcomes in Histological Variants and Non-Urothelial Bladder Cancer: Results of a Multicenter Retrospective Study
IntroductionLess than one-third of bladder cancers are non-pure urothelial carcinoma [with variant histological (VH) or non-urothelial carcinoma (non-UC)] for which no treatment guidelines are available. We aim to evaluate the efficacy of systemic treatments in VH or non-UC bladder cancers.Materials...
Main Authors: | , , , , , , , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2021-05-01
|
Series: | Frontiers in Oncology |
Subjects: | |
Online Access: | https://www.frontiersin.org/articles/10.3389/fonc.2021.671969/full |
id |
doaj-ed8ecba51bbe460394392870f4cd0d98 |
---|---|
record_format |
Article |
spelling |
doaj-ed8ecba51bbe460394392870f4cd0d982021-05-20T07:32:42ZengFrontiers Media S.A.Frontiers in Oncology2234-943X2021-05-011110.3389/fonc.2021.671969671969Treatments Outcomes in Histological Variants and Non-Urothelial Bladder Cancer: Results of a Multicenter Retrospective StudyNicolas Epaillard0Pauline Parent1Yohann Loriot2Pernelle Lavaud3E-B. Vera-Cea4Nieves Martinez-Chanza5Alejo Rodriguez-Vida6Clement Dumont7Rebeca Lozano8Rebeca Lozano9Casilda Llácer10Raffaele Ratta11Stephane Oudard12Constance Thibault13Edouard Auclin14Medical Oncology Department, Hôpital Européen Georges Pompidou, AP-HP, Université de Paris, Paris, FranceGustave Roussy, Université Paris-Sud, Université Paris-Saclay, Villejuif, FranceGustave Roussy, Université Paris-Sud, Université Paris-Saclay, Villejuif, FranceGustave Roussy, Université Paris-Sud, Université Paris-Saclay, Villejuif, FranceMedical Oncology Department, Hospital del Mar, IMIM Research Institute, Barcelona, SpainMedical Oncology Departments, Jules Bordet Institute, Université Libre de Bruxelles, Brussels, BelgiumMedical Oncology Department, Hospital del Mar, IMIM Research Institute, Barcelona, SpainMedical Oncology Department, Hôpital Saint Louis, AP-HP, Université de Paris, Paris, FranceProstate Cancer Clinical Research Unit, Spanish National Cancer Research Centre, Madrid, SpainGenitourinary Oncology Translational Research Group, Instituto de Investigación Biomédica de Málaga (IBIMA), Málaga, SpainGenitourinary Oncology Translational Research Group, Instituto de Investigación Biomédica de Málaga (IBIMA), Málaga, SpainMedical Oncology Department, Hopital Foch, Suresnes, FranceMedical Oncology Department, Hôpital Européen Georges Pompidou, AP-HP, Université de Paris, Paris, FranceMedical Oncology Department, Hôpital Européen Georges Pompidou, AP-HP, Université de Paris, Paris, FranceMedical Oncology Department, Hôpital Européen Georges Pompidou, AP-HP, Université de Paris, Paris, FranceIntroductionLess than one-third of bladder cancers are non-pure urothelial carcinoma [with variant histological (VH) or non-urothelial carcinoma (non-UC)] for which no treatment guidelines are available. We aim to evaluate the efficacy of systemic treatments in VH or non-UC bladder cancers.MaterialsMulticenter retrospective analysis of patients treated for advanced or metastatic VH or non-UC bladder cancers. Primary endpoint was overall response rate (ORR) according to treatment line, regimen and histology subtype. Secondary endpoints were progression-free survival (PFS) and overall survival (OS).ResultsBetween 2005 and 2020, 46 patients from seven centers were included. The median age was 66 years (58.75; 74.75), 65.2% were male and 67.2% presented VH. At first line, the ORR for the entire population was 54.4% and median OS was 21.6 months (95% confidence interval [CI]: 14.2-38.6). The ORR of the 37 patients treated with chemotherapy at first line was 62.2% with median PFS and OS of 7.3 (95% CI: 4.5-8.6) and 21.6 months (95% CI: 14.2-35.7), respectively. Dose dense MVAC and platinum doublet chemotherapy had the highest ORR (71.4% and 65.2%). The 9 patients treated with immunotherapy at first line had an ORR of 22.2%, a median PFS of 3.3 months (95% CI:2.3-NR) and the median OS was not reached (95% CI:13.8-NR). Response to treatment varied depending on the histological sub-types and on the treatment type.ConclusionChemotherapy and immunotherapy have shown to be effective in VH or non-UC cancers, a rare histological subtype for which we currently have very little data in the literature.https://www.frontiersin.org/articles/10.3389/fonc.2021.671969/fullurinary bladder neoplasmsvariant histologydrug therapyimmunotherapymortality |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Nicolas Epaillard Pauline Parent Yohann Loriot Pernelle Lavaud E-B. Vera-Cea Nieves Martinez-Chanza Alejo Rodriguez-Vida Clement Dumont Rebeca Lozano Rebeca Lozano Casilda Llácer Raffaele Ratta Stephane Oudard Constance Thibault Edouard Auclin |
spellingShingle |
Nicolas Epaillard Pauline Parent Yohann Loriot Pernelle Lavaud E-B. Vera-Cea Nieves Martinez-Chanza Alejo Rodriguez-Vida Clement Dumont Rebeca Lozano Rebeca Lozano Casilda Llácer Raffaele Ratta Stephane Oudard Constance Thibault Edouard Auclin Treatments Outcomes in Histological Variants and Non-Urothelial Bladder Cancer: Results of a Multicenter Retrospective Study Frontiers in Oncology urinary bladder neoplasms variant histology drug therapy immunotherapy mortality |
author_facet |
Nicolas Epaillard Pauline Parent Yohann Loriot Pernelle Lavaud E-B. Vera-Cea Nieves Martinez-Chanza Alejo Rodriguez-Vida Clement Dumont Rebeca Lozano Rebeca Lozano Casilda Llácer Raffaele Ratta Stephane Oudard Constance Thibault Edouard Auclin |
author_sort |
Nicolas Epaillard |
title |
Treatments Outcomes in Histological Variants and Non-Urothelial Bladder Cancer: Results of a Multicenter Retrospective Study |
title_short |
Treatments Outcomes in Histological Variants and Non-Urothelial Bladder Cancer: Results of a Multicenter Retrospective Study |
title_full |
Treatments Outcomes in Histological Variants and Non-Urothelial Bladder Cancer: Results of a Multicenter Retrospective Study |
title_fullStr |
Treatments Outcomes in Histological Variants and Non-Urothelial Bladder Cancer: Results of a Multicenter Retrospective Study |
title_full_unstemmed |
Treatments Outcomes in Histological Variants and Non-Urothelial Bladder Cancer: Results of a Multicenter Retrospective Study |
title_sort |
treatments outcomes in histological variants and non-urothelial bladder cancer: results of a multicenter retrospective study |
publisher |
Frontiers Media S.A. |
series |
Frontiers in Oncology |
issn |
2234-943X |
publishDate |
2021-05-01 |
description |
IntroductionLess than one-third of bladder cancers are non-pure urothelial carcinoma [with variant histological (VH) or non-urothelial carcinoma (non-UC)] for which no treatment guidelines are available. We aim to evaluate the efficacy of systemic treatments in VH or non-UC bladder cancers.MaterialsMulticenter retrospective analysis of patients treated for advanced or metastatic VH or non-UC bladder cancers. Primary endpoint was overall response rate (ORR) according to treatment line, regimen and histology subtype. Secondary endpoints were progression-free survival (PFS) and overall survival (OS).ResultsBetween 2005 and 2020, 46 patients from seven centers were included. The median age was 66 years (58.75; 74.75), 65.2% were male and 67.2% presented VH. At first line, the ORR for the entire population was 54.4% and median OS was 21.6 months (95% confidence interval [CI]: 14.2-38.6). The ORR of the 37 patients treated with chemotherapy at first line was 62.2% with median PFS and OS of 7.3 (95% CI: 4.5-8.6) and 21.6 months (95% CI: 14.2-35.7), respectively. Dose dense MVAC and platinum doublet chemotherapy had the highest ORR (71.4% and 65.2%). The 9 patients treated with immunotherapy at first line had an ORR of 22.2%, a median PFS of 3.3 months (95% CI:2.3-NR) and the median OS was not reached (95% CI:13.8-NR). Response to treatment varied depending on the histological sub-types and on the treatment type.ConclusionChemotherapy and immunotherapy have shown to be effective in VH or non-UC cancers, a rare histological subtype for which we currently have very little data in the literature. |
topic |
urinary bladder neoplasms variant histology drug therapy immunotherapy mortality |
url |
https://www.frontiersin.org/articles/10.3389/fonc.2021.671969/full |
work_keys_str_mv |
AT nicolasepaillard treatmentsoutcomesinhistologicalvariantsandnonurothelialbladdercancerresultsofamulticenterretrospectivestudy AT paulineparent treatmentsoutcomesinhistologicalvariantsandnonurothelialbladdercancerresultsofamulticenterretrospectivestudy AT yohannloriot treatmentsoutcomesinhistologicalvariantsandnonurothelialbladdercancerresultsofamulticenterretrospectivestudy AT pernellelavaud treatmentsoutcomesinhistologicalvariantsandnonurothelialbladdercancerresultsofamulticenterretrospectivestudy AT ebveracea treatmentsoutcomesinhistologicalvariantsandnonurothelialbladdercancerresultsofamulticenterretrospectivestudy AT nievesmartinezchanza treatmentsoutcomesinhistologicalvariantsandnonurothelialbladdercancerresultsofamulticenterretrospectivestudy AT alejorodriguezvida treatmentsoutcomesinhistologicalvariantsandnonurothelialbladdercancerresultsofamulticenterretrospectivestudy AT clementdumont treatmentsoutcomesinhistologicalvariantsandnonurothelialbladdercancerresultsofamulticenterretrospectivestudy AT rebecalozano treatmentsoutcomesinhistologicalvariantsandnonurothelialbladdercancerresultsofamulticenterretrospectivestudy AT rebecalozano treatmentsoutcomesinhistologicalvariantsandnonurothelialbladdercancerresultsofamulticenterretrospectivestudy AT casildallacer treatmentsoutcomesinhistologicalvariantsandnonurothelialbladdercancerresultsofamulticenterretrospectivestudy AT raffaeleratta treatmentsoutcomesinhistologicalvariantsandnonurothelialbladdercancerresultsofamulticenterretrospectivestudy AT stephaneoudard treatmentsoutcomesinhistologicalvariantsandnonurothelialbladdercancerresultsofamulticenterretrospectivestudy AT constancethibault treatmentsoutcomesinhistologicalvariantsandnonurothelialbladdercancerresultsofamulticenterretrospectivestudy AT edouardauclin treatmentsoutcomesinhistologicalvariantsandnonurothelialbladdercancerresultsofamulticenterretrospectivestudy |
_version_ |
1721435623306297344 |